Table 2.
Treatment | Mouse # | Anti‐ricin end‐point titer Day 42 | Anti‐ricin end‐point titer Day 84 | Anti‐lumazine synthase end‐point titer Day 84 |
---|---|---|---|---|
1 | 1600 | 800 | 100000 | |
LS_PB10_12 | 2 | 400 | 400 | 50000 |
3 | 400 | 100 | NT* | |
1 | 50 | 100 | NT | |
LS_PB10_12CL | 2 | 0 | 200 | 200000 |
3 | 100 | 3200 | 200000 | |
1 | 200 | 400 | 50000 | |
LS_PB10_34 | 2 | 0 | 100 | 200000 |
3 | 0 | 100 | 100000 | |
1 | 400 | >3200 | 50000 | |
LS_PB10_34CL | 2 | 200 | >3200 | 100000 |
3 | 100 | 100 | 50000 | |
1 | 50 | 3200 | NT | |
LS_PB10_56 | 2 | 50 | 1600 | 50000 |
3 | 0 | 400 | NT | |
1 | 0 | 200 | 50000 | |
LS_PB 10_56CL | 2 | 3200 | 1600 | 200000 |
3 | 100 | 400 | 400000 | |
1 | 200 | 1600 | 100000 | |
LS_PB10_78 | 2 | 100 | 400 | 200000 |
3 | 100 | 800 | 100000 | |
1 | 0 | 200 | 50000 | |
LS_PB10_78CL | 2 | 50 | 200 | 200000 |
3 | 0 | 100 | 100000 |
Groups of mice (n = 3 mice/group) were immunized with 100 µg of LS_PB10 constructs. Serum samples were collected from the mice after the second (Day 42) and third (Day 84) immunizations. NT indicates “not tested” because of insufficient sample volume for analysis. The anti‐ricin end‐point titers for the group treated with LS were not detected and therefore not shown.